论文部分内容阅读
AIM: To describe the incidence of cardiovascular mortality(CVM) in survivors of major cancers and identify its trends over the past two decades. METHODS: We used the surveillance, epidemiology and end-results 19 registry to identify young adults(20-49 years), diagnosed with the following major primary cancers: Lung, breast, liver/intrahepatic bile duct, pancreas, prostate, colorectal, and ovarian from 1990 through 2012 and identified the cumulative incidence of CVM after adjusting for confounding factors. RESULTS: We identified a total of 301923 cancers(breast 173748, lung 38938, colorectal 31722, prostate 22848, ovary 16065, liver 9444, pancreas 9158). A total of 2297(0.8%) of patients had incident CVM. Lung(10-year cumulative CVM 2.4%) and liver(1.73%) cancers had the highest incidence of CVM, while breast(0.6%) and prostate(1.2%) had the lowest CVM mortality, even after multiple adjustments(P < 0.001). Overall, there was a significant improvement in CVM since 1990 [2005-2012 vs 1990-1994, adjusted HR 0.63(0.54-0.72), P < 0.001]. This was driven by improvements in CVM in lung cancers(P = 0.02), breast(P < 0.001), and a trend in ovarian cancer(P = 0.097).There was no statistically significant improvement in CVM among survivors of colorectal, pancreatic, liver, or prostate cancers.CONCLUSION: The risk of CVM differs among different cancers, and is highest among survivors of lung and liver cancers. The incidence of CVM has decreased over the past 2 decades mainly among survivors of lung and breast cancers.
METHODS: We used the surveillance, epidemiology and end-results 19 registry to identify young adults (20-49 years ), diagnosed with the following major primary cancers: Lung, breast, liver / intrahepatic bile duct, pancreas, prostate, colorectal, and ovarian from 1990 through 2012 and identified the cumulative incidence of CVM after adjusting for confounding factors. RESULTS: We identified a total of 301923 cancers (breast 173748, lung 38938, colorectal 31722, prostate 22848, ovary 16065, liver 9444, pancreas 9158). A total of 2297 (0.8%) of patients had incident CVM. Lung had a highest CV of CVM while breast (0.6%) and prostate (1.2%) had the lowest CVM of mortality, even after multiple adjustments (P <0.001). Overall, there was a significant improvement in CVM since 1990 [2005-2012 vs 1990 -1994, adjusted HR 0.63 (0.54-0.72), P <0.001]. This was driven by improvements in CVM in lung cancers (P = 0.02), breast (P <0.001), and a trend in ovarian cancer There was no significant significant in CVM among survivors of colorectal, pancreatic, liver, or prostate cancers. CONCLUSION: The risk of CVMVide among different cancers, and is highest among survivors of lung and liver cancers. The incidence of CVM has decreased over the past 2 decades mainly among survivors of lung and breast cancers.